<DOC>
	<DOCNO>NCT00021944</DOCNO>
	<brief_summary>To test whether novel cardiovascular risk factor relate presence development atherosclerosis macrovascular event Type 2 diabetes mellitus determine whether intensive glucose lower therapy reduce level cardiovascular risk factor .</brief_summary>
	<brief_title>Non-Traditional Cardiovascular Risk Factors Type 2 Diabetes Mellitus - Ancillary VA Study Glycemic Control</brief_title>
	<detailed_description>BACKGROUND : A predominant consequence Type 2 diabetes mellitus accelerate development atherosclerosis related condition . Conventional cardiovascular risk factor explain portion excess risk atherosclerosis population . This ancillary study use study population framework V A Cooperative study `` Glycemic Control Complications DM 2 '' . The Cooperative study prospective , two-arm , randomize , control , multicenter trial ass effect tight glycemic control , achieve intensification treatment , clinical macrovascular microvascular complication patient Type 2 diabetes mellitus poor glycemic control despite pharmacologic therapy . Cooperative study subject multiple site ( 340 subject ) participate trial . The study response initiative `` Ancillary Studies Heart , Lung , Blood Disease Trials '' release National Heart , Lung , Blood Institute June 2000 . DESIGN NARRATIVE : This ancillary study examines non traditional risk factor may contribute accelerate cardiovascular disease Type 2 diabetes effect intensive versus standard glycemic management risk factor . Specific short-term primary aim include determine cross-sectional relationship baseline level presence atherosclerosis measure electron beam compute tomography assessment coronary artery ( CAC ) abdominal aortic calcium ( AAC ) prevalence clinical macrovascular disease . An estimated 340 Cooperative study subject multiple site ask participate additional study . At baseline visit , subject additional blood urine collect ) VLDL , IDL LDL subfractions b ) measure vivo oxidative stress ( oxidized-phospholipids plasma LDL , autoantibodies epitope oxidize LDL , F2-isoprostane level ) c ) AGE-LDL level , ) marker endothelial activation/injury ( PAI-1 , VCAM-1 ICAM-1 ) inflammation ( C-reactive protein fibrinogen ) . Subjects also CAC AAC determine . After enrollment study , participant measurement cardiovascular risk factor repeat six month . Primary secondary macrovascular endpoint identical define VA Cooperative study ( Primary : myocardial infarction , cardiovascular death , stroke , congestive heart failure , invasive vascular therapy ( coronary peripheral ) , amputation due ischemic gangrene ; Secondary : angina pectoris , transient ischemic attack , peripheral artery disease ) . Statistical method , depend specific aim include categorical age sex adjust analysis , t-tests , multiple regression model . Long-term aim include evaluate prospective relationship novel cardiovascular risk factor progression atherosclerosis development macrovascular disease population .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>No eligibility criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>